Key result
Single therapy with systemic or inhaled glucocorticoids showed no consistent clinically relevant association with improved outcomes in infants and young children with acute viral bronchiolitis.
Why the study?
Are glucocorticoids, alone or combined with bronchodilators, associated with reduced admission rates, length of stay, or improvements in clinical severity scores without increased adverse effects in infants and young children with acute viral bronchiolitis?
Population
infants and young children with acute viral bronchiolitis
Design
Review
Authors
Loading...
Supports not using glucocorticoid monotherapy; confirms lack of benefit while leaving combinations open for trials.
Are glucocorticoids, alone or combined with bronchodilators, associated with reduced admission rates, length of stay, or improvements in clinical severity scores without increased adverse effects in infants and young children with acute viral bronchiolitis?
Glucocorticoid monotherapy does not improve clinical outcomes in infants and young children with acute viral bronchiolitis, though combination with nebulized epinephrine may have exploratory benefits in outpatients.
Fernandes et al. (2013) conducted a review in Acute viral bronchiolitis. Glucocorticoids (alone or combined with bronchodilators) was evaluated on Admission rates, length of stay, or improvements in clinical severity scores. Single therapy with systemic or inhaled glucocorticoids showed no consistent clinically relevant association with improved outcomes in infants and young children with acute viral bronchiolitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: